XOMA Royalty
XOMA Royalty is a biotech royalty aggregator that plays a unique role in helping biotech companies achieve their goal of improving human health. They do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. The company focuses on building a diversified portfolio of over 70 assets, providing non-dilutive, non-recourse funding to biotech companies, and operates under a capital-efficient structure. Their strategy involves acquiring rights to future payments, supporting the development of therapeutic assets, and generating value for shareholders through royalty and milestone revenues.
Industries
Nr. of Employees
medium (51-250)
XOMA Royalty
Products
Aggregated portfolio of milestone and royalty rights
A managed collection of contractual rights to milestone payments and royalties tied to a broad set of therapeutic candidates and commercial therapies across multiple stages of development and therapeutic areas.
Aggregated portfolio of milestone and royalty rights
A managed collection of contractual rights to milestone payments and royalties tied to a broad set of therapeutic candidates and commercial therapies across multiple stages of development and therapeutic areas.
Services
Royalty and milestone acquisition
Acquiring contractual rights to future milestone and royalty payments on therapeutic assets in exchange for non-dilutive, non-recourse capital to the seller.
Assets available for licensing / sublicensing
Offering select acquired royalty and milestone interests or development-stage assets for licensing or further monetization by third parties.
Portfolio management and capital deployment advisory
Ongoing management of an aggregated portfolio of royalty and milestone interests, including reinvestment of milestone proceeds and tactical capital deployment to expand the portfolio.
Royalty and milestone acquisition
Acquiring contractual rights to future milestone and royalty payments on therapeutic assets in exchange for non-dilutive, non-recourse capital to the seller.
Assets available for licensing / sublicensing
Offering select acquired royalty and milestone interests or development-stage assets for licensing or further monetization by third parties.
Portfolio management and capital deployment advisory
Ongoing management of an aggregated portfolio of royalty and milestone interests, including reinvestment of milestone proceeds and tactical capital deployment to expand the portfolio.
Expertise Areas
- Royalty acquisition and monetization
- Portfolio management of milestone and royalty interests
- Deal structuring and capital deployment for biotech assets
- Clinical-stage asset evaluation and diligence
Key Technologies
- Phage display and antibody discovery platforms
- Royalty-backed financing structures
- Portfolio aggregation of milestone and royalty rights
- Clinical development stage assessment